about
Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunctionThe limit of plausibility for predictors of response: application to biventricular pacingSignificant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing In Cardiomyopathy.Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry.[It is not easy to examine the causes of fainting. Vasovagal syncope is mostly not dangerous, cardiac syncope is potentially life-threatening]Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm AssociationGuidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm AssociAssociation between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction.Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis.New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribThe effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.Implantable cardioverter-defibrillator treatment and resynchronisation in heart failureEffects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE).Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study.Cardiac resynchronization therapy: Part 1--issues before device implantation.Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions.Effects of cardiac resynchronization therapy on disease progression in chronic heart failure.Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study.Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction.Future directions in cardiac resynchronization therapy.Successful treatment of heart failure with devices requires collaboration.An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure.Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project.Cardiac resynchronization therapy in patients with New York Heart Association class I and II heart failure: an approach to 2010.A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy.Cardiac resynchronization therapy: a breakthrough in heart failure management.2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management.Cardiac resynchronisation therapy optimisation strategies: systematic classification, detailed analysis, minimum standards and a roadmap for development and testing.Current challenges for clinical trials of cardiovascular medical devices.Trials of implantable monitoring devices in heart failure: which design is optimal?Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials.Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure.Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach.Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE).Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
P50
Q27002918-703B4F87-3A2A-4DDD-9463-25FD8AA72AEBQ27007142-772A0322-AC5C-4789-B0EB-DA448BE3197EQ30578523-F79D92B9-9EA2-4CB1-A610-A710B4668060Q30863604-451793F8-3077-451F-9040-30D3F4CD7022Q33144647-13240549-63C4-44EF-871F-64BDDBD20404Q33155459-58882DBF-444B-4629-9B91-9FF31D75C0E0Q33155461-2E31FD22-3BB7-49E4-B720-8B2DC57A288FQ33162947-0100A5E8-74E5-4D40-8488-659E7A62922AQ33164540-CA8B5BA3-0E37-43AB-AA4A-6688B9E4AAE1Q33712583-748B011E-2C5E-4E64-BD1E-505287BBDEF0Q34387086-CDC633D6-92C1-4B5F-BACF-3CC0B42935A1Q34527664-78198726-5E15-4C90-BCAB-EBD1FCF1F79BQ34677347-6010BF27-A661-461F-AF67-936BDB17DE05Q35335608-09E734B2-0850-453C-AFC9-3054EDD3DA4BQ35632179-A3326D75-1502-44E6-B2F5-1B8DEBDF13DAQ36141770-DF23185E-F4E4-4A30-8E6C-96807A5544ECQ36236154-76F148CD-8622-41E0-BF1E-826BD121E8D1Q36258899-28C213CD-B548-400D-85DD-EF553A25B310Q36344631-11433A74-E6B0-4AE6-9D99-C4E9386423C5Q36344636-8E9DC13A-8DAB-4F84-8AA1-3BBDAFF5D33DQ36380523-5114749C-2931-4FF0-B77E-A346A5AB3E98Q36424877-8ADB423B-2606-4236-9CF3-64A83D95042CQ37091011-6E6B872C-7283-4B52-A3D2-869CDAAB4F6CQ37155997-8DC7A852-39A8-4C19-8F08-97DA2E2268E3Q37323953-3FF76ECD-C5B7-4E9F-AED3-A21534CE9D74Q37374291-AEDD73E7-ECA0-4736-8126-FC6E19E53382Q37783741-76D6E815-B383-4F60-A18E-25E08AF83CB7Q37786143-72EA388C-4780-4F51-9873-523E91E6CBC2Q37904878-2A8802E3-C051-4143-B4CF-60A276893273Q38033683-62E6BD83-BB3D-41EA-8764-4B6A9BBD21EFQ38038846-031D16E1-DD96-4FA0-B001-F5F54B7CA368Q38163192-E6F525CD-2F5D-4F76-BE85-A0F1EDB20A8BQ38214839-57455346-C17D-4941-A16E-2E8CF6C2BA33Q38239055-D06473A0-7478-40C4-9E50-89C2CCA6C4D9Q38377406-16B64D39-7697-4EAD-90BB-8413AC5CDEB8Q38378121-30569B3A-B7A8-4C7F-B005-45E6793D91FBQ38382197-1F6DDEDC-5704-4180-B039-15681F49A50AQ38442998-8D472343-1419-457B-94EA-8CCEF10E6401Q38444983-C0B33C15-4B14-4C26-BB13-5205F7F4E00CQ38452103-D6ECE450-7E21-4A1A-BA7F-A92E5DDDB0BA
P50
description
Zweeds onderzoekster
@nl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Cecilia Linde
@ast
Cecilia Linde
@en
Cecilia Linde
@es
Cecilia Linde
@nl
Cecilia Linde
@sl
type
label
Cecilia Linde
@ast
Cecilia Linde
@en
Cecilia Linde
@es
Cecilia Linde
@nl
Cecilia Linde
@sl
prefLabel
Cecilia Linde
@ast
Cecilia Linde
@en
Cecilia Linde
@es
Cecilia Linde
@nl
Cecilia Linde
@sl
P244
P106
P21
P214
196148207632400340292
P244
n2009185194
P27
P31
P496
0000-0002-9039-6023
P735
P7859
lccn-n2009185194